Graham B Cole1, Nagichettiar Satyamurthy1, Jie Liu1, Koon-Pong Wong1, Gary W Small2, Sung-Cheng Huang1, Janez Košmrlj3, Jorge R Barrio4, Andrej Petrič5. 1. Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, CHS B2-086A, 694817, 10833 Le Conte Avenue, Los Angeles, CA, 90095-6948, USA. 2. Department of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuroscience and Human Behavior, UCLA Longevity Center, David Geffen School of Medicine at the University of California, Los Angeles, CA, 90024, USA. 3. Faculty of Chemistry and Chemical Technology, University of Ljubljana, Večna pot 113, SI-1000, Ljubljana, Slovenia. 4. Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, CHS B2-086A, 694817, 10833 Le Conte Avenue, Los Angeles, CA, 90095-6948, USA. jbarrio@mednet.ucla.edu. 5. Faculty of Chemistry and Chemical Technology, University of Ljubljana, Večna pot 113, SI-1000, Ljubljana, Slovenia. andrej.petric@fkkt.uni-lj.si.
Abstract
PURPOSE: Caution is warranted when in vitro results of biomarkers labeled with tritium were perfunctorily used to criticize in vivo data and conclusions derived with the same tracers labeled with positron emitters and positron emission tomography (PET). This concept is illustrated herein with the PET utilization of [18F]FDDNP, a biomarker used for in vivo visualization of β-amyloid and tau protein neuroaggregates in humans, later contradicted by in vitro data reported with [3H]FDDNP. In this investigation, we analyze the multiple factors involved in the experimental design of the [3H]FDDNP in vitro study that led to the erroneous interpretation of results. PROCEDURE: The present work describes full details on the synthesis, characterization, purity, and kinetics of radiolytic stability of [3H]FDDNP. The optimal in vitro conditions for detecting tau and β-amyloid protein aggregates using macroscopic and microscopic autoradiography with both [18F]FDDNP and [3H]FDDNP are also presented. Macroscopic autoradiography determinations were performed with [3H]FDDNP of verified purity using established methods described previously in the literature. RESULTS: The autoradiographic results using phosphate buffered saline (PBS) with less than 1 % EtOH and pure, freshly prepared [3H]FDDNP compared with the earlier reported data using [3H]FDDNP of undetermined purity and PBS in 10 % EtOH demonstrate the critical importance of rigorous experimental design for meaningful in vitro determinations. [18F]FDDNP binding to both amyloid plaques and neurofibrillary tangles was confirmed by amyloid and tau immunohistochemical stains of adjacent tissues. CONCLUSIONS: This work illustrates the sensitivity of in vitro techniques to various experimental conditions and underscores that conclusions obtained from translational in vitro to in vivo determinations must always be performed with extreme care to avoid wrong interpretations that can be perpetuated and assumed without further analysis.
PURPOSE: Caution is warranted when in vitro results of biomarkers labeled with tritium were perfunctorily used to criticize in vivo data and conclusions derived with the same tracers labeled with positron emitters and positron emission tomography (PET). This concept is illustrated herein with the PET utilization of [18F]FDDNP, a biomarker used for in vivo visualization of β-amyloid and tau protein neuroaggregates in humans, later contradicted by in vitro data reported with [3H]FDDNP. In this investigation, we analyze the multiple factors involved in the experimental design of the [3H]FDDNP in vitro study that led to the erroneous interpretation of results. PROCEDURE: The present work describes full details on the synthesis, characterization, purity, and kinetics of radiolytic stability of [3H]FDDNP. The optimal in vitro conditions for detecting tau and β-amyloid protein aggregates using macroscopic and microscopic autoradiography with both [18F]FDDNP and [3H]FDDNP are also presented. Macroscopic autoradiography determinations were performed with [3H]FDDNP of verified purity using established methods described previously in the literature. RESULTS: The autoradiographic results using phosphate buffered saline (PBS) with less than 1 % EtOH and pure, freshly prepared [3H]FDDNP compared with the earlier reported data using [3H]FDDNP of undetermined purity and PBS in 10 % EtOH demonstrate the critical importance of rigorous experimental design for meaningful in vitro determinations. [18F]FDDNP binding to both amyloid plaques and neurofibrillary tangles was confirmed by amyloid and tau immunohistochemical stains of adjacent tissues. CONCLUSIONS: This work illustrates the sensitivity of in vitro techniques to various experimental conditions and underscores that conclusions obtained from translational in vitro to in vivo determinations must always be performed with extreme care to avoid wrong interpretations that can be perpetuated and assumed without further analysis.
Authors: Eric D Agdeppa; Vladimir Kepe; Jie Liu; Gary W Small; Sung-Cheng Huang; Andrej Petric; Nagichettiar Satyamurthy; Jorge R Barrio Journal: Mol Imaging Biol Date: 2003 Nov-Dec Impact factor: 3.488
Authors: Julie C Price; William E Klunk; Brian J Lopresti; Xueling Lu; Jessica A Hoge; Scott K Ziolko; Daniel P Holt; Carolyn C Meltzer; Steven T DeKosky; Chester A Mathis Journal: J Cereb Blood Flow Metab Date: 2005-11 Impact factor: 6.200
Authors: A J Wakefield; S H Murch; A Anthony; J Linnell; D M Casson; M Malik; M Berelowitz; A P Dhillon; M A Thomson; P Harvey; A Valentine; S E Davies; J A Walker-Smith Journal: Lancet Date: 1998-02-28 Impact factor: 79.321
Authors: Paul W Thompson; Liang Ye; Jennifer L Morgenstern; Lucia Sue; Thomas G Beach; Duncan J Judd; Nicholas J Shipley; Vincenzo Libri; Andrew Lockhart Journal: J Neurochem Date: 2009-02-13 Impact factor: 5.372
Authors: Lojze M Smid; Vladimir Kepe; Harry V Vinters; Mara Bresjanac; Tatsushi Toyokuni; Nagichettiar Satyamurthy; Koon-Pong Wong; Sung-Cheng Huang; Daniel H S Silverman; Karen Miller; Gary W Small; Jorge R Barrio Journal: J Alzheimers Dis Date: 2013 Impact factor: 4.472
Authors: Vladimir Kepe; Yvette Bordelon; Adam Boxer; Sung-Cheng Huang; Jie Liu; Frederick C Thiede; John C Mazziotta; Mario F Mendez; Natacha Donoghue; Gary W Small; Jorge R Barrio Journal: J Alzheimers Dis Date: 2013 Impact factor: 4.472
Authors: Beatrix Krause-Sorio; Prabha Siddarth; Kelsey T Laird; Linda Ercoli; Katherine Narr; Jorge R Barrio; Gary Small; Helen Lavretsky Journal: Int Psychogeriatr Date: 2020-01-23 Impact factor: 3.878